We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glycated Albumin Levels in Tears Allow Noninvasive Glucose Testing

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
Image: Glycated albumin levels in tears allows for noninvasive glucose testing (Photo courtesy of The University of Melbourne).
Image: Glycated albumin levels in tears allows for noninvasive glucose testing (Photo courtesy of The University of Melbourne).
The glucose test helps determine if a person’s glucose level is too high or too low, which can indicate the presence of Type 2 diabetes and other medical conditions. The two most common types of glucose testing are the fasting plasma glucose test and the random plasma glucose test.

Glycated albumin is albumin that has been glycated (bound to sugar). Albumin is the most common type of protein found in blood (~80% of circulating proteins) and is replaced in the body about every 20-25 days. Excessive glycation of albumin causes irreversible damage to organs and their vasculature.

Scientists at the University of Tokyo (Tokyo, Japan) recruited 100 adults (mean age, 50.87 years; 71% men) with diabetes from outpatient and inpatient practices. Participants had tear samples collected at the same time as a blood sampling tests. The team measured glycated albumin levels in tears with liquid chromatography-mass spectrometry, whereas blood sample levels were measured through an enzymatic method.

The investigators reported that glycated albumin levels were appropriately measured in 99 of 100 participants. Initial results showed a correlation between glycated albumin levels in blood and those measured in tears (beta = 0.722; 95% CI, 0.585-0.859). The correlation between tear levels and blood levels remained after adjustments for age, sex, nephropathy stage and obesity (beta = 0.738; 95% CI, 0.594-0.882). HbA1c was not assessed in the study.

Masakazu Aihara, MD, PhD, a project research associate and lead author of the study, said, “To achieve strict glucose control preventing diabetic complications, many patients take HbA1c tests in hospitals and some take self-monitoring of blood glucose. Continuous glucose monitoring has also been put into practical use, but all of these measurement methods are invasive, and it is a burden on the patients. We focus on tears, which can be collected with noninvasive ways, and found that the glycated albumin levels in tears and blood had strong correlation. Since glycated albumin reflects two week average blood glucose levels, it does not need to be measured as frequently as self-monitoring and can be used in the same way as HbA1c tests.”

Dr. Aihara added “The correlation of glycated albumin levels in tears and blood that we found in this study was much stronger than that of glucose levels, and a measurement method of tear glycated albumin can be used in clinical practice.” The study was presented at the European Association for the Study of Diabetes virtual meeting, held 21-25 September, 2020.

Related Links:
University of Tokyo

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Hepatitis B Assay
Monolisa HBs Ag ULTRA Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.